In the November/December 2015 issue of PharmaVOICE, Jeff Aroy comments on how the application of sensors, connectivity, and continuous monitoring can revolutionize drug development in some areas. To read the article, click here.
Why diabetes and other common health conditions matter for men on prostate cancer hormone therapy
Key takeaways Men with prostate cancer are more likely to die from heart disease, not cancer. Patients who start androgen deprivation therapy (ADT) are...